NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB): TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE STOCK OF Y-MABS THERAPEUTICS, INC. ("Y-MABS") BETWEEN OCTOBER 6, 2020 AND OCTOBER 28, 2022, BOTH DATES INCLUSIVE. You are receiving this N ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. Mr. Pfreundschuh p ...

Mr. Pfreundschuh will be based in Y-mAbs' New York and New Jersey offices. Forward-Looking Statements DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. "I am thrilled to join the Y-mAbs team during this pivotal time for the company," said Mr. Pfreundschuh. "With a solid financial foundation fueled by the growing commercial success of DANYELZA® on a global scale, I believe Y-mAbs is well positioned to further advance our SADA-PRIT technology platform and materially change the way w ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-Investor Relations Michael Rossi - President and Chief Executive Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Bill Maughan - Canaccord Genuity Nick Unan - BMO Capital Markets David Nierengarten - Wedbush Securities Operator Good morning, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 (Address of principal executive offices) (Zip Code) (646)-885-8505 (Registrant's telephone number, including area c ...

Exhibit 99.1 Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments New York, NY, May 7, 2024 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the "Company" or "Y- mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024. "We continued to make meanin ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Conference Call March 1, 2024 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Bo Kruse - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America David Nierengarten - Wedbush Securities Lukas Shumway - BMO Capital Markets Operator Good morning and welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Results Conference Call November 14, 2023 9:00 AM ET Company Participants Courtney Dugan - Vice President of Investor Relations Michael Rossi - President and Chief Executive Officer Thomas Gad - Chief Business Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Steen Lisby - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Bill Maughan - Canaccord Genuity Mike Ulz - Morg ...